ALLO
Allogene Therapeutics Inc
NASDAQ · Biotechnology
$1.69
+0.06 (+3.68%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.71M | 52.93M | 41.75M |
| Net Income | 7.77M | 8.17M | 5.40M |
| EPS | — | — | — |
| Profit Margin | 14.7% | 15.4% | 12.9% |
| Rev Growth | +19.4% | -7.3% | -1.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 170.60M | 170.56M | 157.74M |
| Total Equity | 120.38M | 116.15M | 124.94M |
| D/E Ratio | 1.42 | 1.47 | 1.26 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 12.72M | 14.19M | 11.69M |
| Free Cash Flow | 7.78M | 12.29M | 5.60M |